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Abstract
Uremia-associated anorexia may be related to altered levels of long chain n-6 and n-3 
polyunsaturated fatty acid (PUFA) derived circulating endocannabinoids (EC) and EC-like 
compounds that are known to mediate appetite. Our study's hypothesis was that such molecules 
are associated with appetite in patients with end-stage renal disease. A cross-sectional 
observational study was performed in 20 chronic hemodialysis patients (9 females, 11 males) and 
10 healthy female controls in whom appetite was assessed using the Simplified Nutritional 
Appetite Questionnaire (SNAQ) and blood drawn in the fasting (and when applicable) pre-dialysis 
state. Blood levels of PUFA and EC were also measured. Higher blood levels of the long chain n-6 
fatty acid 20:4n6 (arachidonic acid) and lower levels of the long chain n-3 fatty acid 20:5n3 
(eicosapentaenoic acid) were observed in female hemodialysis patients compared to controls. No 
differences were observed between male and female patients. In female study participants strong 
correlations between specific EC-like compounds and total SNAQ scores were noted, including 
with the n-6 PUFA derived linoleoyl ethanolamide (L-EA; ρ= -0.60, P<0.01) and the n-3 PUFA 
derived docosahexaenoyl ethanolamide (DH-EA; ρ= 0.63, P<0.01). The L-EA:DH-EA ratio was 
most strongly associated with the SNAQ score (ρ= -0.74, P≤0.001), and its questions associated 
with appetite (ρ= -0.69, P≤0.01) and satiety (ρ= -0.81, P≤0.001). These findings support a link 
between circulating EC and appetite in hemodialysis patients.
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 1. Introduction
The development of uremia from kidney failure is associated with anorexia and an increased 
risk of nutritional deficiencies [1-3]. Uremia may lead to loss of appetite by altering levels of 
circulating molecules known to mediate appetite like leptin, ghrelin, and neuropeptide Y [4]. 
Whether uremia also contributes to anorexia via the endocannabinoid (EC) system is 
unknown. Endocannabinoid signaling (ECS) is a potent mediator of food intake and 
influences energy metabolism through its regulation of orexigenic and anorectic molecules 
(including some of those mentioned above) and neural pathways [5-7]. EC mediators 
oversee complex crosstalk between the central and peripheral nervous system and the gut, 
muscle, and adipose tissue [8]. Elucidation of this process has led to new drug therapies for 
appetite-related disorders [9].
Of particular relevance, ECS activation via the brain cannabinoid receptor CB1 leads to 
stimulation of appetite [10]. Precursor molecules for the most investigated EC ligands of the 
cannabinoid receptor are derived from the polyunsaturated fatty acid (PUFA) arachidonic 
acid (20:4n-6), whereas EC-like ligands showing contrary and competing effects [11], are 
products of various saturated, monounsaturated and polyunsaturated fatty acids including the 
n-3 PUFA eicosapentaenoic acid (20:5n-3) and docosapentaenoic acid (22:5n-3) [10, 12].
Basic information on the physiology and blood content of EC and EC-like metabolites in 
patients with kidney failure is lacking. We therefore performed a pilot study in hemodialysis 
patients to characterize EC blood levels and examine their relationship to appetite. The study 
hypothesis, tested by measuring circulating levels of EC and their fatty acid precursors and 
comparing them to measurements of appetite [10], was that blood EC levels correlate with 
appetite.
 2. Methods and Materials
 2.1 Participants
Study participants were recruited from outpatient hemodialysis units affiliated with Indiana 
University School of Medicine, Indianapolis, IN, and healthy controls from the Indiana 
University-Purdue University Indianapolis (IUPUI) campus, Indianapolis, IN, in early 2012. 
The IUPUI campus institutional review board approved the protocol and all participants 
gave written informed consent after reviewing a written summary of the study plan. 
Inclusion criteria for the hemodialysis patients were age 18 or older and ability to provide 
informed consent. Exclusion criterion was hospitalization for any reason within the past 3 
months.
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 2.2 Appetite Questionnaire and Clinical Information
The Simplified Nutritional Appetite Questionnaire (SNAQ) was developed to assess appetite 
and predict weight loss. SNAQ has been validated in healthy adults, including elderly adults 
and those in long-term care residences [13, 14] and used in the chronic kidney disease 
population [15]. SNAQ consists of four questions, individually scored from 1 to 5, in order 
to give a range of 4-20 points, with lower scores predicting a greater risk of weight loss 
within six months [13]. Demographic and medical data were obtained from each participant 
through simple questionnaires. The SNAQ survey was administered at the time of blood 
draw.
 2.3 Measurement of Fatty Acids and Endocannabinoids
A fasting blood draw was obtained immediately before a mid-week dialysis session from the 
dialysis tubing in each dialysis patient. Control subjects also had blood drawn in the fasting 
state. Blood was collected in EDTA-preserved tubes. PMSF, a fatty acid amide hydrolase 
(FAAH) inhibitor, was added to a set of samples to prevent breakdown of anandamide (i.e. 
arachidonoyl ethanolamide (A-EA)). However, results of the analysis with and without 
PMSF were not significantly different so the data were combined. Plasma fatty acid levels of 
polar lipids were measured by gas chromatographic analysis as previously described [16]. 
Fatty acid data reflect fatty acid methyl esters (FAME) as weight % and the values are 
presented as means ± SD of plasma polar fatty acids. Authentic external standards were used 
for the peak identification in GC output chromatograms. The sensitivity of the GC detector 
is at 10 ng/peak [17]. Plasma EC measurements were performed on 250 μL aliquots using 
ultra-performance liquid chromatography-electrospray tandem mass spectrometry as 
previously described [18].
 2.4 Statistical analyses
Standard descriptive statistics were used. Group differences were evaluated using 2-tailed t-
tests after data normalization using imDEV v 1.4.2 [19]. Correlation between EC levels and 
SNAQ scores were assessed using Pearson correlations calculated in Microsoft Excel. P-
values less than 0.05 were regarded as significantly different.
 3. Results
Twenty chronic hemodialysis patients and ten healthy female controls were recruited for the 
study. Mean age and body mass indices were not significantly different between patients and 
controls, whereas SNAQ scores were depressed in patients in a borderline significant manner 
(P=0.051; Table 1). Plasma fatty acids were measured in all subjects and the principal PUFA 
that act as EC precursors are shown in Table 2. Plasma levels of arachidonic (20:4n-6) and 
eicosapentaenoic (20:5n-3) acids were higher and lower, respectively, in female 
hemodialysis patients compared to female controls. No difference was noted for these PUFA 
between male and female patients.
An array of EC were measured in the plasma of each of the twenty female hemodialysis 
patients and controls including the acyl ethanolamides of palmitate, stearate, oleate, 
linoleate, alpha-linoleate, di homo-gamma-linolenate, arachidonate, docosaheptanoate, and 
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docosahexenoate, and the 1- and 2-mono-acylglycerols of oleate, linoleate, and arachidonate 
(data not shown). The oleoyl ethanolamide (O-EA; 14.8 ± 3.8 vs. 22.6 ± 9.7, P=0.030) and 
linoleoyl ethanolamide (L-EA; 6.1 ± 2.1 vs. 9.7 ± 3.7, P=0.016) were elevated ∼1.5 fold in 
hemodialysis patients. The relationship between EC levels and SNAQ score components 
were then evaluated (Table 3). The n-6 linoleic acid-derived EC linoleoyl ethanolamide (L-
EA) and the n-3 docosahexaenoic acid-derived EC docosahexaenoylethanolamine (DH-EA) 
were negatively and positively correlated with the SNAQ score, respectively. The correlation 
between EC and satiety was the strongest among all the four sub-components of the SNAQ 
score (Table 3). Calculating the ratio of L-EA:DH-EA generated a very strong (ρ= -0.74, 
P<0.001) metabolic correlate to the SNAQ Score (Figure 1). The relationship between L-EA 
and DH-ES and SNAQ are presented in a Supplemental Figure. Of note, there were no 
differences in circulating DH-EA levels (0.64±0.09 vs 0.68±0.10, P=0.33) between the 
healthy females and female hemodialysis patients.
 4. Discussion
Anorexia is a serious, well-recognized complication of uremia. The goal of our exploratory 
study, the first such study in patients with kidney failure, was to determine if a relationship 
in chronic hemodialysis patients exists between appetite and circulating blood levels of EC. 
We found a linear relationship between appetite and two EC-like compounds, L-EA and 
DH-EA, and their ratio. This appears to support our study hypothesis. This relationship 
showed the strongest association to the satiety component of the appetite score and is 
consistent with the appetite suppression previously associated with L-EA in rodents [12]. 
Interestingly, while elevated levels of the reported satiety factor oleoyl ethanolamide [20] 
were detected in female hemodialysis patients, the association with satiety was weaker 
(P<0.5) and no correlation with appetite scores was observed.
While the precise mechanisms by which EC and EC-like compounds mediate appetite are 
still being elucidated, it is clear that these effects occur at the hypothalamus, mesolimbic 
system, brainstem, and gut levels [6]. We do know that palmitoyl, oleoyl, and linoleoyl 
ethanolamides are poor cannabinoid receptor ligands and peroxisome proliferator activated 
receptor-α-dependent appetite suppressants in rats, with the latter two molecules showing 
similar potencies [12, 21, 22]. In contrast, cannabinoid receptor activation is an important 
positive stimulator of dopaminergic reward seeking [23] and directly linked to appetite 
regulation [24], and DH-EA is a known cannabinoid receptor ligand [25]. In light of this 
information it is reasonable to suspect that circulating fatty acid ethanolamides such as L-EA 
and DH-EA could correlate to the appetite scores in the manner we have shown, and that the 
L-EA:DH-EA ratio could demonstrate an even stronger association with appetite.
Therefore, while this pilot study does not map out the precise mediating effects of EC in 
dialysis patients, it does suggest that circulating EC can reflect and perhaps influence 
appetite in this population. It also confirms our previous finding that blood levels of long 
chain n-3 PUFA are lower and long chain n-6 PUFA higher in hemodialysis patients 
compared to controls [26]. Such a state could result in relatively reduced production of EC-
like ligands generated from long chain n-3 PUFA as compared to those from long chain n-6 
PUFA, leading to an elevated L-EA:DH-EA ratio such as what we report. In light of the 
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robust negative relationship between L-EA and appetite that we observed, this imbalance 
could help explain the anorexia of uremia. The strong inverse link between the L-EA:DH-
EA ratio and appetite also suggests that n-3 PUFA derived-ECs may antagonize the putative 
anorectic effects of L-EA. Therefore, strategies to manipulate EC levels by using EC 
agonists [10] or supplementing long-chain n-3 PUFA to increase n-3 EC-like compounds 
(e.g. DH-EA) should be explored as an approach to improve appetite in anorectic dialysis 
patients.
Our pilot study has several strengths. The SNAQ screening tool has a reasonably high 
sensitivity (82%) and specificity (85%) to detect poor appetite [13]. Dialysis study 
participants with recent hospitalizations were excluded to avoid concomitant illnesses that 
could influence the SNAQ score and blood draws were uniform throughout the study. 
Analytic chemical measurements were performed using powerful mass spectrometry 
techniques to assess a broad array of known EC and EC-like compounds. While the mean 
BMI of our study population was in the obese range, the range of BMI was quite wide, thus 
allowing us to study appetite along a spectrum of body habitus. Future studies could 
examine the relationship between EC and appetite in patients who have not yet initiated 
dialysis at a time when the uremic milieu has not been affected by maintenance dialysis. The 
study also has limitations. It was modest in size and cross-sectional in design, thus 
preventing the assessment of causality. In addition, the analysis of EC did not include male 
hemodialysis patients (or a male control group) due to funding limitations.
In conclusion, our pilot study identified EC-like compounds that were significantly 
associated with appetite and satiety in chronic hemodialysis patients. In light of the well-
established relationship between the N-acyl ethanolamides and appetite, further research to 
confirm our preliminary findings in male dialysis patients, ascertain whether alterations in 
EC signaling play an important role in the anorexia of uremia, and determine whether PUFA 
supplementation can influence this role, are reasonable next steps.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Endocannabinoid ratio of L-EA:DH-EA to SNAQ score in female participants Correlation of 
composite appetite score with the L-EA:DH-EA ratio among all female subjects (healthy 
controls and patients, n = 19, P≤ 0.001).
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Table 1
Characteristics of the study participants
Female Controls (n=10) Hemodialysis Patients
Female (n=9) Male (n=11) Totals (n=20)
Age (yrs) 55 ± 5 59 ± 13 52 ± 15 55 ± 14
Diabetes (%) 20 22 55 40
Time on dialysis (yrs) 10 ± 11 7 ± 6 8 ± 8
Body mass index (kg/m2) 31 ± 5 31 ± 9 30 ± 10 30 ± 10
 Range 24-40 16 - 44 20 - 50
3 month weight change (kg) ---- 0.8 ± 1.8 -0.1 ± 1.9 0.4 ± 1.9
6 month weight change (kg) ---- 0.7 ± 1.3 0.4 ± 2.9 0.5 ± 2.3
SNAQ scores by question
 Appetite 3.8 ± 1.0 3.2 ± 1.4 3.9 ± 0.8 3.6 ± 1.1
 Satiety 3.4 ± 0.8 2.2 ± 1.2 3.7 ± 0.7 3.1 ± 1.2
 Food taste 3.9 ± 0.7 3.7 ± 0.9 4.2 ± 0.8 4.0 ± 0.8
 Normal intake 3.8 ± 0.6 2.9 ± 0.8 3.5 ± 0.8 3.2 ± 0.8
 Total 14.9 ± 2.6 12.0 ± 3.4 15.3 ± 2.1 13.8 ± 3.1
Values are means ± SD
There were no statistically significant (P<0.05) differences between groups
Nutr Res. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Friedman et al. Page 10
Ta
bl
e 
2
Pl
as
m
a 
fa
tty
 a
ci
d 
co
m
po
sit
io
n 
of
 p
ol
ar
 li
pi
ds
 o
f t
he
 st
ud
y 
pa
rt
ic
ip
an
ts
*
Fa
tt
y 
ac
id
Fe
m
a
le
 C
on
tr
o
ls 
(n
=1
0)
H
em
od
ia
ly
sis
 P
a
tie
nt
s
P 
va
lu
e 
(fe
ma
le 
co
nt
ro
ls 
vs
. p
at
ie
nt
s)
P 
va
lu
e 
(fe
ma
le 
vs
. m
ale
 pa
tie
nt
s)
Fe
m
a
le
 (n
=9
)
M
al
e 
(n
=1
1)
Li
no
le
ic
 a
ci
d 
(18
:2n
-6)
18
.1
6 
± 
3.
29
18
.4
0 
± 
2.
28
19
.9
1±
 3
.6
3
0.
86
0.
29
A
ra
ch
id
on
ic
 a
ci
d 
(20
:4n
-6)
11
.4
7 
± 
1.
71
13
.6
1 
± 
1.
87
13
.3
5 
± 
2.
61
0.
01
9
0.
81
Ei
co
sa
pe
nt
ae
no
ic
 a
ci
d 
(20
:5n
-3)
0.
71
 ±
 0
.2
8
0.
38
 ±
 0
.0
9
0.
38
 ±
 0
.1
3
0.
00
5
0.
94
D
oc
os
ah
ex
ae
n
o
ic
 a
ci
d 
(22
:6n
-3)
3.
11
 ±
 1
.5
7
2.
68
 ±
 0
.7
8
2.
20
 ±
 0
.7
7
0.
46
0.
19
R
at
io
 o
f l
on
g 
ch
ai
n 
n-
6/
n-
3†
3.
72
 ±
 1
.2
9
4.
65
 ±
 0
.8
6
4.
93
 ±
 0
.6
6
0.
08
7
0.
42
*
Va
lu
es
 a
re
 m
ea
ns
 ±
 S
D
 o
f w
ei
gh
t p
er
ce
nt
ag
es
.
† L
Cn
-6
=2
0:
2n
-6
+2
0:
3n
-6
+2
0:
4n
-6
+2
2:
4n
-6
+2
2:
5n
-6
; L
Cn
-3
=2
0:
5n
-3
+2
2:
5n
-3
+2
2:
6n
-3
N
B:
 D
iff
er
en
ce
s b
et
w
ee
n 
m
al
e 
pa
tie
nt
s a
nd
 c
on
tro
l f
em
al
es
 fo
r 2
0:
4n
-6
 an
d 
20
:5
n-
3 
w
er
e s
ig
ni
fic
an
t (
P ≤
 0.
01
).
Nutr Res. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Friedman et al. Page 11
Ta
bl
e 
3
Pl
as
m
a 
ac
yl
 e
th
an
ol
am
id
e 
co
rr
el
at
io
ns
 to
 S
NA
Q 
Sc
or
es
 in
 fe
m
al
e 
su
bje
cts
*
A
pp
et
ite
Sa
tie
ty
Fo
o
d 
Ta
st
e
N
or
m
al
 In
ta
ke
To
ta
l S
NA
Q
P-
EA
-
0.
04
-
0.
09
-
0.
03
-
0.
01
-
0.
04
S-
EA
-
0.
33
-
0.
63
*
*
-
0.
29
-
0.
14
-
0.
41
O
-E
A
-
0.
28
-
0.
50
*
-
0.
37
-
0.
22
-
0.
42
L-
EA
-
0.
44
-
0.
64
*
*
-
0.
36
-
0.
51
*
-
0.
60
*
*
aL
-E
A
-
0.
22
-
0.
46
*
-
0.
29
-
0.
47
*
-
0.
43
D
G
LA
-E
A
-
0.
1
0.
01
-
0.
39
-
0.
18
-
0.
15
A
-E
A
-
0.
05
-
0.
02
0.
01
-
0.
2
-
0.
07
D
-E
A
-
0.
36
-
0.
37
-
0.
24
-
0.
46
-
0.
43
D
H
-E
A
0.
63
*
*
0.
59
*
*
0.
54
*
0.
31
0.
63
*
*
L-
EA
:D
H
-E
A
-
0.
69
*
*
-
0.
81
*
*
*
-
0.
49
*
-
0.
45
-
0.
74
*
*
*
*
Va
lu
es
 a
re
 S
pe
ar
m
an
's 
co
rre
la
tio
n 
ρ v
al
ue
s a
fte
r d
at
a 
tra
ns
fo
rm
at
io
n 
to
 a
 m
or
e 
no
rm
al
 d
ist
rib
u
tio
n.
Si
gn
ifi
ca
nc
e 
of
 c
or
re
la
tio
ns
 a
re
 in
di
ca
te
d 
at
*
*
*
p<
0.
00
1,
*
*
p<
0.
01
, a
nd
*
p<
0.
05
 u
sin
g 
a 2
-ta
ile
d 
as
se
ss
m
en
t.
P-
EA
 - 
pa
lm
ito
yl
 e
th
an
ol
am
id
e;
 S
-E
A
 - 
ste
ar
oy
l e
th
an
ol
am
id
e;
 O
-E
A
, o
le
oy
l e
th
an
ol
am
id
e;
 L
-E
A
, l
in
ol
eo
yl
 e
th
an
ol
am
id
e;
 α
L-
EA
, a
lp
ha
-li
no
le
no
yl
 e
th
an
ol
am
id
e;
 D
G
LA
-E
A
 - 
di
ho
m
o-
ga
m
m
a-
lin
ol
en
oy
l 
et
ha
no
la
m
id
e;
 A
-E
A
 - 
ar
ac
hi
do
no
yl
 e
th
an
ol
am
id
e;
 D
-E
A
 - 
do
co
sa
te
tra
en
oy
l e
th
an
ol
am
id
e;
 D
H
-E
A
 - 
do
co
sa
he
x
ae
n
o
yl
 e
th
an
ol
am
id
e
Nutr Res. Author manuscript; available in PMC 2017 July 01.
